Originally developed to treat type 2 diabetes, recent studies have shown that Semaglutide can also aid in weight loss for individuals struggling with obesity
Research has found that about half of GLP-1 users stop taking the drugs within a year, so the question of whether the weight loss sticks is prudent
Their disclosed restrictions: Bupropion / Semaglutide / Tirzepatide / Liraglutide / Metformin / NAD+ supplements / Naltrexone are not available in LA or MS
Ro is expanding its weight-loss offering with the addition of Eli Lillys newly approved oral GLP-1, Foundayo (orforglipron), giving patients a second daily pill alternative to injectable therapies and further intensifying competition in the rapidly evolving obesity treatment market
Albert Lawson, Aggravated Flight, Charge Dismissed, Jefferson, 2019 State v
doi:10.1038/s41392-024-01931-z 2